Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626093 · ClinicalTrials.gov registry record · Phase 4
'Effect of CRT on Defibrillation Threshold Estimates' Study
A Phase 4 study of Sudden Cardiac Death, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 4
- Development phase
- 77
- Enrollment target
- 2
- Study locations
NCT00626093: Completed Phase 4 study of Sudden Cardiac Death, sponsored by Abbott Medical Devices.
NCT00626093 is a Phase 4 study of Sudden Cardiac Death that has completed, run by Abbott Medical Devices. The registered enrollment target is 77 participants, below the 1,412-participant average among 9 other Sudden Cardiac Death trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00626093, a Phase 4 study of Sudden Cardiac Death, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 77 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this prospective study is to evaluate the effect of cardiac resynchronization therapy (CRT) on the defibrillation threshold (DFT) estimates in cardiac resynchronization therapy defibrillators (CRT-D) patients. The hypothesis of the study is that defibrillation threshold (DFT) will decrease with 6 months of cardiac resynchronization therapy (CRT).
Primary Outcome
All patients underwent defibrillation threshold testing at cardiac resynchronization therapy-defibrillator (CRT-D) implant and then at 6 months. The outcome measure is the difference in DFT (defibrillation threshold) in volts between implant and 6 months.
Conditions Studied
Interventions
- DEVICE Cardiac Resynchronization Therapy - Defibrillator (CRT-D)
Study Locations (2)
California
- Pacific Heart Institute - Santa Monica
Colorado
- Penrose Hospital - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-04 |
| Phase | Phase 4 |
What the finished NCT00626093 record still lists
NCT00626093 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 1,412-participant average among 9 other Sudden Cardiac Death trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Sudden Cardiac Death appearing as the primary indexed condition, and to 1 intervention - of which Cardiac Resynchronization Therapy - Defibrillator (CRT-D) is the first listed.
NCT00626093 reports a single indexed study location in California, Colorado.
Frequently Asked Questions
What is clinical trial NCT00626093 about?
NCT00626093 is a clinical study titled "'Effect of CRT on Defibrillation Threshold Estimates' Study". The purpose of this prospective study is to evaluate the effect of cardiac resynchronization therapy (CRT) on the defibrillation threshold (DFT) estimates in cardiac resynchronization therapy defibrillators (CRT-D) patients. The hypothesis of the study is that defibrillation threshold (DFT) will dec...
What is the current status of trial NCT00626093?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 77 participants. The study started on 2008-01. Estimated completion is 2010-04.
What conditions does trial NCT00626093 study?
This clinical trial studies the following conditions: Sudden Cardiac Death.
What interventions are being tested in trial NCT00626093?
The interventions under investigation include: Cardiac Resynchronization Therapy - Defibrillator (CRT-D) (DEVICE).
Who is sponsoring clinical trial NCT00626093?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00626093 being conducted?
This trial has 2 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sudden Cardiac Death
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00626093's enrollment target sits among peer trials
77 10th of 9 the lowest of 9 other Sudden Cardiac Death trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sudden Cardiac Death trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
RECRUITING · Phase 4
-
Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications
COMPLETED · Phase 4
-
Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk
RECRUITING
-
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
RECRUITING · NA
-
Mayo AVC Registry and Biobank
RECRUITING
-
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia